| Date Filed | Type | Description |
| 02/26/2019 |
GN
| BioTime to Present New Data From OpRegen® and Vision Restoration Programs at the Association for Research in Vision and Ophthalmology Annual Meeting (ARVO 2019) |
| 01/04/2019 |
GN
| BioTime Announces Management Changes Concurrent With Participation at 2019 J.P. Morgan Healthcare Conference and 2019 Biotech Showcase |
| 03/14/2018 |
GN
| Research Report Identifies Supernus Pharmaceuticals, Celestica, Global Blood Therapeutics, BioTime, CyberArk Software, and Tivity Health, Inc. with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement |
| 08/02/2017 |
BW
| BioTime Reports Second Quarter Results and Recent Corporate Accomplishments |
| 07/20/2017 |
BW
| BioTime, Inc. to Announce Second Quarter 2017 Results on August 2, 2017 |
| 06/14/2017 |
BW
| BioTime's Renevia® Achieves Primary Endpoint in European Pivotal Trial |
| 04/26/2017 |
BW
| BioTime, Inc. to Announce First Quarter 2017 Results on May 10, 2017 |
| 02/23/2017 |
BW
| BioTime, Inc. to Announce Fourth Quarter and Fiscal 2016 Results on March 16, 2017 |
| 08/19/2011 |
BW
| BioTime Receives NIH Approval for Four GMP Human Embryonic Stem Cell Lines |
| 07/21/2011 |
BW
| BioTime CEO Dr. Michael West to Present at the Agora Financial Investment Symposium 2011 |
| 07/15/2011 |
BW
| BioTime Receives $335,900 SBIR Grant |
| 06/29/2011 |
BW
| BioTime Announces Appointment of Chief Commercial Officer |
| 05/10/2011 |
BW
| BioTime Announces Issuance of U.S. Glycosan Hydrogel Patent |
| 05/05/2011 |
BW
| BioTime Announces First Quarter 2011 Financial Results and Corporate Developments |
| 04/12/2011 |
BW
| BioTime Presents Data at FABS 2011 on the Restoration of Cell Lifespan Using iPS Cell Technology |
| 04/05/2011 |
BW
| BioTime and XenneX Form LifeMap Sciences, Inc. to Create Roadmap for Regenerative Medicine |
| 03/22/2011 |
BW
| BioTime Announces the Closing of the Merger of Glycosan BioSystems with OrthoCyte Corporation |
| 03/15/2011 |
BW
| BioTime Announces Fourth Quarter and Fiscal Year 2010 Financial Results and Corporate Developments |
| 03/04/2011 |
BW
| BioTime CEO Michael West to Present at French-American Biotech Symposium, San Francisco, April 11-12, 2011 |
| 02/14/2011 |
BW
| BioTime Announces Agreement To Acquire Glycosan BioSystems |
| 10/26/2010 |
BW
| BioTime Expands Corporate Headquarters |
| 10/22/2010 |
BW
| BioTime's CEO Michael West Presents 12 New ACTCellerateTM Cell Lines and New PureStemTM Products Slated for Launch in 2011 at GTCbio Stem Cell Conference Today |
| 10/14/2010 |
BW
| BioTime's CEO Michael West to Speak at GTCbio and Unveil 12 New Diverse Cell Lines to be Launched November 1, 2010 |
| 10/12/2010 |
BW
| BioTime Announces Stock Ticker Symbol Change and Extension of Warrant Expiration Date |
| 09/16/2010 |
BW
| BioTime CEO Dr. Michael West and CMO Dr. David Jin to Present Keynote Addresses at The Sixth Chinese Congress in Regenerative Medicine and Stem Cell Therapy in Suzhou, P.R. China |
| 09/13/2010 |
BW
| BioTime CEO Dr. Michael West to Present at Stem Cells USA & Regenerative Medicine Congress 2010 |
| 09/08/2010 |
BW
| BioTime Announces Executive Management Changes |
| 08/26/2010 |
BW
| BioTime to Launch Seven New Embryonic Progenitor Cell Lines on September 1, 2010 |
| 08/19/2010 |
BW
| BioTime Raises $9.2 Million in Warrant Discount Offer |
| 08/16/2010 |
BW
| BioTime Announces Second Quarter 2010 Financial Results and Recent Corporate Developments |
| 07/21/2010 |
BW
| BioTime Announces Addition of New Stem Cell Lines to Its Product Portfolio |
| 07/19/2010 |
BW
| BioTime, Inc. Provides Financial Information about Its Acquisition of ES Cell International Pte Ltd. |
| 07/09/2010 |
BW
| BioTime CEO Dr. Michael West to Present at the Agora Financial Investment Symposium 2010 |
| 07/06/2010 |
BW
| BioTime Announces Passing of Board Director Dr. Robert N. Butler |
|